Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sentinel Lymph Nodes for Breast Carcinoma A Paradigm Shift</title><author><name sortKey="Maguire, Aoife" sort="Maguire, Aoife" uniqKey="Maguire A" first="Aoife" last="Maguire">Aoife Maguire</name></author><author><name sortKey="Brogi, Edi" sort="Brogi, Edi" uniqKey="Brogi E" first="Edi" last="Brogi">Edi Brogi</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">27472237</idno><idno type="pmc">5027875</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027875</idno><idno type="RBID">PMC:5027875</idno><idno type="doi">10.5858/arpa.2015-0140-RA</idno><date when="2016">2016</date><idno type="wicri:Area/Pmc/Corpus">003685</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">003685</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Sentinel Lymph Nodes for Breast Carcinoma A Paradigm Shift</title><author><name sortKey="Maguire, Aoife" sort="Maguire, Aoife" uniqKey="Maguire A" first="Aoife" last="Maguire">Aoife Maguire</name></author><author><name sortKey="Brogi, Edi" sort="Brogi, Edi" uniqKey="Brogi E" first="Edi" last="Brogi">Edi Brogi</name></author></analytic><series><title level="j">Archives of pathology & laboratory medicine</title><idno type="ISSN">0003-9985</idno><idno type="eISSN">1543-2165</idno><imprint><date when="2016">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec id="S1"><title>Context</title><p id="P1">Sentinel lymph node biopsy has been established as the new standard of care for axillary staging in most patients with invasive breast carcinoma. Historically, all patients with a positive sentinel lymph node biopsy result underwent axillary lymph node dissection. Recent trials show that axillary lymph node dissection can be safely omitted in women with clinically node negative, T1 or T2 invasive breast cancer treated with breast-conserving surgery and whole-breast radiotherapy. This change in practice also has implications on the pathologic examination and reporting of sentinel lymph nodes.</p></sec><sec id="S2"><title>Objective</title><p id="P2">To review recent clinical and pathologic studies of sentinel lymph nodes and explore how these findings influence the pathologic evaluation of sentinel lymph nodes.</p></sec><sec id="S3"><title>Data Sources</title><p id="P3">Sources were published articles from peer-reviewed journals in PubMed (US National Library of Medicine) and published guidelines from the American Joint Committee on Cancer, the Union for International Cancer Control, the American Society of Clinical Oncology, and the National Comprehensive Cancer Network.</p></sec><sec id="S4"><title>Conclusions</title><p id="P4">The main goal of sentinel lymph node examination should be to detect all macrometastases (>2 mm). Grossly sectioning sentinel lymph nodes at 2-mm intervals and evaluation of one hematoxylin-eosin–stained section from each block is the preferred method of pathologic evaluation. Axillary lymph node dissection can be safely omitted in clinically node-negative patients with negative sentinel lymph nodes, as well as in a selected group of patients with limited sentinel lymph node involvement. The pathologic features of the primary carcinoma and its sentinel lymph node metastases contribute to estimate the extent of non–sentinel lymph node involvement. This information is important to decide on further axillary treatment.</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">7607091</journal-id><journal-id journal-id-type="pubmed-jr-id">758</journal-id><journal-id journal-id-type="nlm-ta">Arch Pathol Lab Med</journal-id><journal-id journal-id-type="iso-abbrev">Arch. Pathol. Lab. Med.</journal-id><journal-title-group><journal-title>Archives of pathology & laboratory medicine</journal-title></journal-title-group><issn pub-type="ppub">0003-9985</issn><issn pub-type="epub">1543-2165</issn></journal-meta><article-meta><article-id pub-id-type="pmid">27472237</article-id><article-id pub-id-type="pmc">5027875</article-id><article-id pub-id-type="doi">10.5858/arpa.2015-0140-RA</article-id><article-id pub-id-type="manuscript">NIHMS807420</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Sentinel Lymph Nodes for Breast Carcinoma A Paradigm Shift</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Maguire</surname><given-names>Aoife</given-names></name><degrees>MB, BCh, BAO, MRCPI, FRCPath</degrees></contrib><contrib contrib-type="author"><name><surname>Brogi</surname><given-names>Edi</given-names></name><degrees>MD, PhD</degrees></contrib><aff id="A1">Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York</aff></contrib-group><author-notes><corresp id="FN1">Reprints: Edi Brogi, MD, PhD, Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065 (<email>brogie@mskcc.org</email>)</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>7</day><month>8</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>8</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>9</month><year>2016</year></pub-date><volume>140</volume><issue>8</issue><fpage>791</fpage><lpage>798</lpage><pmc-comment>elocation-id from pubmed: 10.5858/arpa.2015-0140-RA</pmc-comment>
<abstract><sec id="S1"><title>Context</title><p id="P1">Sentinel lymph node biopsy has been established as the new standard of care for axillary staging in most patients with invasive breast carcinoma. Historically, all patients with a positive sentinel lymph node biopsy result underwent axillary lymph node dissection. Recent trials show that axillary lymph node dissection can be safely omitted in women with clinically node negative, T1 or T2 invasive breast cancer treated with breast-conserving surgery and whole-breast radiotherapy. This change in practice also has implications on the pathologic examination and reporting of sentinel lymph nodes.</p></sec><sec id="S2"><title>Objective</title><p id="P2">To review recent clinical and pathologic studies of sentinel lymph nodes and explore how these findings influence the pathologic evaluation of sentinel lymph nodes.</p></sec><sec id="S3"><title>Data Sources</title><p id="P3">Sources were published articles from peer-reviewed journals in PubMed (US National Library of Medicine) and published guidelines from the American Joint Committee on Cancer, the Union for International Cancer Control, the American Society of Clinical Oncology, and the National Comprehensive Cancer Network.</p></sec><sec id="S4"><title>Conclusions</title><p id="P4">The main goal of sentinel lymph node examination should be to detect all macrometastases (>2 mm). Grossly sectioning sentinel lymph nodes at 2-mm intervals and evaluation of one hematoxylin-eosin–stained section from each block is the preferred method of pathologic evaluation. Axillary lymph node dissection can be safely omitted in clinically node-negative patients with negative sentinel lymph nodes, as well as in a selected group of patients with limited sentinel lymph node involvement. The pathologic features of the primary carcinoma and its sentinel lymph node metastases contribute to estimate the extent of non–sentinel lymph node involvement. This information is important to decide on further axillary treatment.</p></sec></abstract></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0036850 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0036850 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.31. |  |